First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

ClinicalTrials.gov ID: NCT01697072

Public ClinicalTrials.gov record NCT01697072. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin \& capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma

Study identification

NCT ID: NCT01697072
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Amgen; Industry
Enrollment: 609 participants

Conditions and interventions

Conditions

Gastric Cancer

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2012 (Type not available)
Primary completion: Nov 2014 (Actual)
Completion: Aug 2015 (Actual)
Last update posted: Feb 9, 2016

2012 – 2015

United States locations

U.S. sites: 16
U.S. states: 12
U.S. cities: 16

Facility	City	State	ZIP	Site status
Research Site	Tucson	Arizona	85724	—
Research Site	Aurora	Colorado	80045	—
Research Site	Pueblo	Colorado	81008	—
Research Site	Chicago	Illinois	60637	—
Research Site	Baltimore	Maryland	21231	—
Research Site	Woodbury	Minnesota	55125	—
Research Site	Henderson	Nevada	89052	—
Research Site	New York	New York	10065	—
Research Site	Rochester	New York	14642	—
Research Site	Greensboro	North Carolina	27403	—
Research Site	Winston-Salem	North Carolina	27103	—
Research Site	Pittsburgh	Pennsylvania	15232	—
Research Site	Nashville	Tennessee	37232	—
Research Site	Bedford	Texas	76022	—
Research Site	Dallas	Texas	75246	—
Research Site	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 173 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01697072, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 9, 2016 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01697072 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →